Embattled Appen (ASX:APX) share price bounces despite a top broker downgrade

This broker has given its verdict on the Appen share price.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Appen share price is the top performer on the ASX 200 despite broker downgrade 
  • JPMorgan cut its rating on the shares to “neutral” and lowered its price target by nearly half to $7 a share 
  • Doubts over Appen’s ability to hit its 2026 targets and near-term uncertainty are the main reasons for the downgrade 

The Appen Ltd (ASX: APX) share price rallied even after a leading broker cut its recommendation on its shares.

The artificial intelligence (AI) software developer jumped 5% to $6.97 this morning – making it the top performer on the S&P/ASX 200 Index (ASX: XJO).

And in case you are wondering, the Iluka Resources Limited (ASX: ILU) share price and Paladin Energy Ltd (ASX: PDN) share price are in second and third spot.

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.

Image source: Getty Images

Appen share price bucks downgrade news

But the surge in the Appen share price could puzzle some as it comes after JPMorgan lowered its rating on the shares to "neutral" from "overweight".

The broker made the downgrade following Appen's disappointing results, which missed JPMorgan's estimates.

The weakness was driven largely by Appen's New Markets division. This business failed to live up to growth expectations.

Lofty targets and near-term uncertainty

Investors would have also been put off by management's decision not to issue any more short-term guidance. If there's one thing that markets hate, it's uncertainty.

Management will instead focus on its 2026 targets and that means an increase in reinvestment in the business, noted JPMorgan.

"We believe APX's 2026 target to double revenue seems very ambitious given mgmt's recent track record," said the broker.

"Although the stock has likely oversold in the short term, the lack of visibility on growth and heightened levels of reinvestment means we would prefer to stay on the sidelines until mgmt starts delivering on their guidance."

Looking past US for support

Appen is counting on growth in non-global customers to contribute meaningfully to its 2026 targets. The number of such customers, which are essentially non-US tech giants, is tipped to grow at a 35% compound annual growth rate (CAGR).

That means this group will be contributing to around a third of Appen's revenue.

"The guidance also implies mid-single digit growth in APX's Global Services revenues," added JPMorgan.

"At this point in time we believe these targets appear to be very ambitious, given revenue growth has slowed from 11% in FY20 to 8% in FY21."

What is the Appen share price worth?

JPMorgan cut its 12-month price target on the Appen share price to $7 from $13.50 a share.

But given the 59% collapse in the Appen share price over the past year, some shareholders might just be relieved that the downgrade wasn't more severe.

Motley Fool contributor Brendon Lau owns Iluka Resources Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Appen Ltd. The Motley Fool Australia owns and has recommended Appen Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Morgans says hold BHP shares and buy this ASX 200 stock      

Let's see what the broker is saying about these stocks this week.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

3 ASX 200 shares just upgraded to strong buy — here's what the brokers are saying

Do any of these ASX 200 stocks appeal to you?

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Two men look excited on the trading floor as they hold telephones to their ears and one points upwards.
Broker Notes

Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares

Brokers reveal their latest ratings and reviews on 3 ASX 200 stocks.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

Buy, hold, sell: Macquarie, Boss Energy, CBA shares

The market looks set to endure a sixth consecutive day in the red.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Guess which ASX 200 share could rise 90% according to Bell Potter

Let's see what the broker is saying about this stock this week.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

These ASX 200 shares could rise 25% to 70%

Morgans expects big returns from these top stocks.

Read more »

ASX 200 shares broker downgrade origami paper fortune teller with buy hold sell and dollar sign options
Broker Notes

Down 42% in a year, are Boss Energy shares now a bargain buy?

A leading analyst provides his outlook for Boss Energy’s beaten down shares.

Read more »